World Journal of Gastrointestinal Oncology最新文献

{"title":"Molecular surveillance-informed personalized multidisciplinary therapy achieves prolonged survival in a patient with Lynch syndrome-associated colorectal cancer: A case report.","authors":"Xin-Xin Xu, Yun-He Gao, Cheng-Zhou Du, Xiao-Xin Gao, Peng Chen, Rui-Fang Fan, Hong-Tao Li, Zhi Qiao","doi":"10.4251/wjgo.v17.i6.106316","DOIUrl":"10.4251/wjgo.v17.i6.106316","url":null,"abstract":"<p><strong>Background: </strong>Lynch syndrome (LS), an autosomal dominant genetic disorder, is distinguished by germline mutations in the DNA mismatch repair genes, including <i>MLH1</i>. These mutations confer an elevated risk for the development of colorectal cancer (CRC) and an array of other malignancies. Timely detection, facilitated by genetic profiling and stringent molecular surveillance, is crucial. It enables the implementation of customized therapeutic strategies, which have the potential to markedly enhance patient outcomes. Despite its significant public health impact, LS is frequently underdiagnosed, underscoring the necessity for increased vigilance and the adoption of precision medicine tactics.</p><p><strong>Case summary: </strong>This case presentation focuses on a 54-year-old male patient with a strong familial predisposition to colon cancer, who was identified to have LS-associated multiple colorectal neoplasms. Utilizing a comprehensive, multidisciplinary therapeutic strategy that encompassed precision medicine, immunotherapy with pembrolizumab, and stringent molecular residual disease monitoring, we effectively managed his advanced CRC. This tailored approach led to the achievement of sustained clinical remission exceeding 30 months, illustrating the promise of personalized treatment protocols in optimizing outcomes for individuals with LS and associated colorectal malignancies.</p><p><strong>Conclusion: </strong>A synergistic, multidisciplinary approach is essential for managing LS-associated CRC, advocating for personalized care pathways in precision medicine.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106316"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Charged multivesicular body protein 7 was identified as a prognostic biomarker correlated with metastasis in colorectal cancer.","authors":"Jin-Rui Wei, Yi-Na Ouyang, Meng-Ting Tang, Jia-Zhen Yuan, Pei-Li Wang, Li-He Jiang, Li-Chuan Wu","doi":"10.4251/wjgo.v17.i6.105967","DOIUrl":"10.4251/wjgo.v17.i6.105967","url":null,"abstract":"<p><strong>Background: </strong>Metastasis is the main reason leading to death in colorectal cancer (CRC) and about 25% of CRC patients developed metastasis when first diagnosed. Thus, unveiling biomarkers of CRC metastasis is of great significance.</p><p><strong>Aim: </strong>To reveal biomarkers of CRC metastasis.</p><p><strong>Methods: </strong>Weighted gene co-expression network analysis was conducted to identify metastatic biomarkers in CRC through a systematic analysis of the GSE29621 dataset. Comprehensive validation was performed subsequently using publicly available datasets from The Cancer Genome Atlas and Gene Expression Omnibus and supplemented with experimental verification in CRC cell lines. Moreover, the identified hub gene charged multivesicular body protein 7 (CHMP7) was further subjected to clinical correlation analysis <i>via</i> Kaplan-Meier survival curves and Gene Set Enrichment Analysis to assess its prognostic significance and potential mechanistic involvement in CRC progression.</p><p><strong>Results: </strong>CHMP7 was identified as a key metastatic biomarker of CRC which displayed lower expression in CRC tissues, especially in CRC patients with metastasis and CRC cell lines with high metastasis potential. The expression of CHMP7 was significantly correlated with normal, metastatic tumor, pathologic stage, and lymphatic invasion (<i>P</i> < 0.05). CRC patients with higher expression of CHMP7 exhibited better overall survival. Besides, Gene Set Enrichment Analysis results showed that CHMP7 might be involved in metastatic related pathways.</p><p><strong>Conclusion: </strong>Our results indicate that CHMP7 might be a prognostic biomarker correlated with CRC metastasis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105967"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and literature review.","authors":"Xiang-Lei Kong, Xi-Wei Lu, Si-Qi Dong, Jiao Liu, Lei Zheng, Lan-Lan Chen, Zi-Hui An, Li-Ming Gao, Jun-Li Cao","doi":"10.4251/wjgo.v17.i6.107568","DOIUrl":"10.4251/wjgo.v17.i6.107568","url":null,"abstract":"<p><strong>Background: </strong>Descending duodenal adenocarcinoma (DDA) is a rare malignancy of the digestive system, typically characterized by microsatellite instability-high (MSI-H). Pembrolizumab is a monoclonal antibody that has been approved for the treatment of MSI-H solid tumors in China.</p><p><strong>Case summary: </strong>We present the case of a 55-year-old female patient diagnosed with DDA. Biopsy findings indicated MSI-H status with high expression of programmed cell death-ligand 1 (PD-L1). The patient was unable to undergo immediate surgery due to multiple metastatic lymph nodes in the retroperitoneum. After one cycle of the SOX (S-1 + oxaliplatin) chemotherapy regimen, the patient's performance status significantly declined, and she experienced active gastrointestinal bleeding. Following active communication with the patient's family, pembrolizumab treatment was initiated. After two cycles of treatment, the disease was assessed as a partial response. A positron emission tomography/computed tomography scan performed after two years of treatment indicated a clinical complete response (CCR). The patient maintained this CCR for four years. She has now discontinued pembrolizumab for over one year, and no disease recurrence has been observed during re-examination.</p><p><strong>Conclusion: </strong>Patients with MSI-H DDA exhibiting high PD-L1 expression who are treated with pembrolizumab can achieve sustained CCR.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"107568"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a nomogram for predicting postoperative venous thromboembolism risk in patients with hepatocellular carcinoma.","authors":"Chun-Rong Chen, Hong-Liang Jin, Qian-Jie Xu, Yu-Liang Yuan, Zu-Hai Hu, Ya Liu, Hai-Ke Lei","doi":"10.4251/wjgo.v17.i6.105790","DOIUrl":"10.4251/wjgo.v17.i6.105790","url":null,"abstract":"<p><strong>Background: </strong>Few studies have specifically modeled the risk of venous thromboembolism (VTE) for postoperative hepatocellular carcinoma (HCC) patients, although HCC is the third leading cause of cancer death worldwide. This study aimed to develop and validate a nomogram that accurately predicts the risk of VTE in patients after HCC surgery.</p><p><strong>Aim: </strong>To develop and validate a nomogram to accurately predict the risk of VTE in postoperative HCC patients by integrating clinical and laboratory risk factors. The model seeks to provide a user-friendly tool for identifying high-risk individuals who may benefit from targeted anticoagulation therapy, thereby improving clinical decision-making and patient outcomes.</p><p><strong>Methods: </strong>Data from patients who underwent HCC surgery at Chongqing University Cancer Hospital in China were analyzed. Through univariate and multivariate logistic regression analyses, independent risk factors for VTE were identified and integrated into a nomogram. The predictive performance of the nomogram was assessed <i>via</i> receiver operating characteristic curves, calibration curves, decision curve analysis and other relevant metrics.</p><p><strong>Results: </strong>Of 905 postoperative HCC patients were included in the study. The nomogram incorporated eight independent risk factors for VTE: Karnofsky Performance Scale, base disease, cancer stage (tumor-node-metastasis), chemotherapy, D-dimer concentration, white blood cell count, hemoglobin, and fibrinogen. The C-index for the nomogram model was 0.825 in the training cohort and 0.820 in the validation cohort, indicating good discriminative ability. Calibration plots of the model revealed high concordance between the predicted probabilities and observed outcomes.</p><p><strong>Conclusion: </strong>We developed and validated a novel nomogram that can accurately estimate the risk of VTE in individual postoperative HCC patients. This model can identify high-risk patients who may benefit from targeted anticoagulation therapy.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105790"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinesin family member 14 in digestive tract malignancies: Oncogenic mechanisms, clinical implications, and therapeutic prospects.","authors":"De-Hui Li, Chang Qiao, Yu-Tong Han, Jian-Li Ge","doi":"10.4251/wjgo.v17.i6.105062","DOIUrl":"10.4251/wjgo.v17.i6.105062","url":null,"abstract":"<p><p>In this editorial, we comment on the article by Qin <i>et al</i>, recently published in the <i>World Journal of Gastrointestinal Oncology</i>. Malignant tumors of the digestive tract represent a significant health threat. Kinesin family member 14 (KIF14), a critical kinesin, is pivotal in the proliferation, migration, and invasion of tumor cells. It has emerged as a focal point in recent studies of malignant tumors in the digestive tract. This article reviews the current research on KIF14 within these tumors and details its significant role in tumor cell behaviors, including proliferation, apoptosis, migration, invasion, and angiogenesis, alongside the regulatory mechanisms of the associated intracellular signaling pathways. Additionally, it explores the clinical value of KIF14 as a potential biomarker for early diagnosis, disease monitoring, and prognostic evaluation in malignant tumors of the digestive tract. The article concludes by introducing the potential regulatory role of traditional Chinese medicine, aiming to combine the strengths of both modern and traditional medical approaches to enhance treatment outcomes and prognosis for patients with these tumors.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105062"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy.","authors":"Zheng-Wen Wang, Cai-Yan Pan, Cang-Long Wei, Hui Liao, Xiao-Po Zhang, Cai-Yun Zhang, Lei Yu","doi":"10.4251/wjgo.v17.i6.105570","DOIUrl":"10.4251/wjgo.v17.i6.105570","url":null,"abstract":"<p><strong>Background: </strong>Finding active lead anti-hepatocellular carcinoma compounds from traditional Chinese medicine has important research value.</p><p><strong>Aim: </strong>To assess the detailed mechanism of oxocrebanine, a compound separated from the traditional Chinese medicinal plant <i>Stephania hainanensis</i> H.S. Lo et Y. Tsoong, and to evaluate its inhibition of the proliferation of human hepatocellular carcinoma cells <i>via</i> apoptosis and autophagy.</p><p><strong>Methods: </strong>MTT, BrdU labeling, and colony formation assays were used to assess the inhibitory effect of oxocrebanine on the growth and proliferation of human hepatocellular carcinoma Hep3B2.1-7 cells. Flow cytometry was used to detect the effect of oxocrebanine on the apoptosis of Hep3B2.1-7 cells. Western blotting was used to assess the expression of apoptosis-related proteins in Hep3B2.1-7 cells. The aforementioned methods were also used to evaluate the effects of oxocrebanine on cell proliferation, autophagy markers, and autophagy-related protein expression levels after adding autophagy inhibitor 3-mA. Furthermore, to verify the anti-hepatocellular carcinoma effect of oxocrebanine <i>in vivo</i>, a nude mouse model was used to investigate the inhibitory effect of oxocrebanine treatment and its mechanism. Apoptosis was detected using a TUNEL assay and the expression of microtubule-associated protein 1 LC3 in tumor specimens was assessed using immunohistochemistry.</p><p><strong>Results: </strong>Oxocrebanine effectively inhibited the growth of Hep3B2.1-7 cells, whilst upregulating the protein expression of cleaved caspase-3, downregulating poly(ADP-ribose) polymerase 1 protein expression, increasing the levels of Bax and Bcl-2 antagonist/killer 1 protein expression, and decreasing the levels of Bcl-2 and myeloid cell leukemia 1 protein expression, which could promote apoptosis in Hep3B2.1-7 cells. Oxocrebanine promoted the transformation of LC3-I to LC3-II in Hep3B2.1-7 cells, suggesting the occurrence of autophagy, whilst the autophagy inhibitor 3-MA could reverse this process. Oxocrebanine was also shown to reduce the phosphorylation levels of the eukaryotic translation initiation factor 4EBP1 and ribosomal protein S6 kinase B1 (P70S6K), two downstream effector molecules in the PI3K/Akt/mTOR pathway, inducing autophagy in Hep3B2.1-7 cells. Moreover, the tumor-bearing nude mouse experiment indicated that oxocrebanine effectively inhibited the growth of Hep3B2.1-7 cells <i>in vivo</i>. The results of the TUNEL assay and immunohistochemistry also revealed that oxocrebanine induced apoptosis <i>in vivo</i> and increased the expression level of LC3, an autophagy marker.</p><p><strong>Conclusion: </strong>Oxocrebanine can inhibit the proliferation of human hepatocellular carcinoma cells by promoting apoptosis and inducing autophagy <i>in vitro</i> and <i>in vivo</i>.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105570"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential mechanism of <i>Camellia luteoflora</i> against colon adenocarcinoma: An integration of network pharmacology and molecular docking.","authors":"Yu-Di Dong, Xi-Ming Wu, Wan-Qing Liu, You-Wu Hu, Hong Zhang, Wan-Di Fang, Qing Luo","doi":"10.4251/wjgo.v17.i6.105782","DOIUrl":"10.4251/wjgo.v17.i6.105782","url":null,"abstract":"<p><strong>Background: </strong><i>Camellia luteoflora</i> is a unique variety of <i>Camellia</i> in China which is only distributes in Chishui City, Guizhou Province and Luzhou City, Sichuan Province. Its dried leaves are used by local residents as tea to drink with light yellow and special aroma for health care. It has high potential economic medicinal value. Colon adenocarcinoma (COAD) is the third most frequent malignancy and its incidence and mortality is increasing. However, the current common treatments for COAD bring great side effects. In recent years, natural products and their various derivatives have shown significant potential to supplement conventional therapies and to reduce associated toxicity while improving efficacy. In order to overcome the limitations of traditional treatment methods, the global demand and development of natural anti-COAD drugs were increasingly hindered.</p><p><strong>Aim: </strong>To investigate the potential targets and mechanisms of <i>Camellia luteoflora</i> anti-COAD.</p><p><strong>Methods: </strong>Nuclear magnetic resonance and mass spectrometry was used to identified the compounds of <i>Camellia luteoflora</i>. Network pharmacology analysis and survival analysis was used in this study to investigate the anti-COAD effect and mechanism of <i>Camellia luteoflora</i>.</p><p><strong>Results: </strong>Firstly, a total of 13 compounds were identified. Secondly, 10 active ingredients for 204 potential targets were screened and protein-protein interaction analysis showed that <i>TP53</i>, <i>STAT3</i>, <i>ESR1</i>, <i>MAPK8</i>, <i>AKR1C3</i>, <i>RELA</i>, <i>CYP19A1</i>, <i>CYP1A1</i>, <i>JUN and CYP17A1</i> were hub targets. GO and KEGG enrichment analyses revealed that <i>Camellia luteoflora</i> exerted anti-COAD effect through multiple functions and pathways. Then, the analysis of survival and stage indicated that <i>TP53</i> was highly expressed in COAD and the overall survival of high-<i>TP53</i> and high-CYP19A1 COAD patients was significantly shorter than the low group and there was significant difference in MAPK and RELA expression between different stages. Finally, the molecular docking results demonstrated the binding affinities and sites between active ingredients and <i>TP53</i>, STAT3, ESR1.</p><p><strong>Conclusion: </strong>Our study systematically demonstrated the potential anti-COAD mechanism of <i>Camellia luteoflora</i> and provided a theoretical basis for its further application in the COAD treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105782"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of preoperative fibrinogen, neutrophil-to-lymphocyte ratio, serum alpha-fetoprotein, and prealbumin for patients with primary liver cancer undergoing transarterial chemoembolization.","authors":"Qi-Qi Liu, Ya-Dong Li, Jia-Xin Chen, Lin-Lin Zhang, Rong-Chun Guan, Wei Zhao, Ling-Yu Meng","doi":"10.4251/wjgo.v17.i6.103198","DOIUrl":"10.4251/wjgo.v17.i6.103198","url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a major cause of cancer-related mortality. Transarterial chemoembolization (TACE) is a key palliative option for unresectable HCC. However, prognostic outcomes after TACE vary significantly. This study evaluated the prognostic value of the fibrinogen and neutrophil-to-lymphocyte ratio (F-NLR) score, serum alpha-fetoprotein (AFP), and prealbumin (PA) in patients undergoing TACE.</p><p><strong>Aim: </strong>To investigate the prognostic significance of F-NLR score, AFP, and PA in patients undergoing TACE.</p><p><strong>Methods: </strong>Variables such as F-NLR score, AFP, PA, and other clinical indicators were assessed. Follow-ups determined prognosis as good or poor. Statistical assessments, including receiver operating characteristic analyses, were performed to evaluate the prognostic significance and develop an integrated predictive model.</p><p><strong>Results: </strong>A retrospective analysis of 162 patients with primary liver cancer undergoing TACE was conducted. Low F-NLR scores and AFP levels and high PA were significantly associated with a good prognosis. The combined model, which integrated F-NLR, AFP, and PA, demonstrated a favorable prognostic predictive capability, with an area under the curve of 0.933.</p><p><strong>Conclusion: </strong>Preoperative F-NLR, AFP, and PA are valuable prognostic predictors in patients with HCC undergoing TACE.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"103198"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer.","authors":"Ti-Hong Qiu, Hong-You Wen, Yi-Long Huang","doi":"10.4251/wjgo.v17.i6.104592","DOIUrl":"10.4251/wjgo.v17.i6.104592","url":null,"abstract":"<p><strong>Background: </strong>Advanced gastric cancer is characterized by fast tumor growth and aggressive biological behavior. During neoadjuvant chemotherapy, patients are at risk of distant metastasis or local progression. Anemia is a frequent complication in these patients.</p><p><strong>Aim: </strong>To analyze whether changes in hemoglobin and hematocrit can predict the survival and efficacy of neoadjuvant chemotherapy in patients with advanced gastric cancer.</p><p><strong>Methods: </strong>The clinical data of 185 patients with advanced gastric cancer admitted to the Third Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital, Chengdu, China, between January 2016 and January 2021, were retrospectively analyzed. All patients underwent a tegafur + oxaliplatin + apatinib chemotherapy regimen. According to the efficacy of chemotherapy, they were divided into an effective group (complete or partial response, <i>n</i> = 121) and an ineffective group (stable disease or disease progression, <i>n</i> = 64). The factors related to chemotherapy efficacy in patients with advanced gastric cancer were analyzed by univariate and logistic multivariate analyses. The 3-year survival rates of the patients with different hemoglobin and hematocrit levels were compared.</p><p><strong>Results: </strong>Univariate analysis showed that the proportion of patients with a tumor diameter > 5 cm, non-tubular adenocarcinoma, lymph node metastasis, hematocrit < 33%, low mean red blood cell (RBC) protein content, low RBC distribution width, hemoglobin < 107 g/L, and platelets > 266 × 10⁹/L in the ineffective group were significantly higher than those in the effective group (<i>P</i> < 0.05). Logistic multivariate analysis showed that a tumor diameter > 5 cm, lymph node metastasis, ≤ 3 chemotherapy cycles, hematocrit < 33%, and hemoglobin < 107 g/L are risk factors for neoadjuvant chemotherapy failure in advanced gastric cancer (<i>P</i> < 0.05). The 1-year, 2-year, and 3-year survival rates in the effective group were 93.39%, 83.47%, and 60.33%, respectively. These rates were significantly higher than those in the ineffective group (<i>P</i> < 0.05). The 1-year, 2-year, and 3-year survival rates of patients with hematocrit < 33% were 74.67%, 49.33%, and 29.33%, respectively, which were significantly lower than those of patients with hematocrit ≥ 33% (<i>P</i> < 0.05). The 1-year, 2-year, and 3-year survival rates of patients with hemoglobin < 107 g/L were 80.39%, 58.82%, and 39.22%, respectively, which were significantly lower than those of patients with hemoglobin ≥ 107 g/L (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Hematocrit < 33% and hemoglobin < 107 g/L are risk factors for chemotherapy failure in patients with advanced gastric cancer. They are associated with poorer prognosis and reduced 3-year survival rates.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"104592"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer in children infected with <i>Helicobacter pylori</i>.","authors":"Xia Gong, Cen Chen, Jun-Fei Shen","doi":"10.4251/wjgo.v17.i6.103632","DOIUrl":"10.4251/wjgo.v17.i6.103632","url":null,"abstract":"<p><strong>Background: </strong>This retrospective study aimed to define associations between <i>Helicobacter pylori</i> (<i>H. pylori</i>) in childhood and risk factors for gastric cancer with special emphasis on the role of family history of cancer.</p><p><strong>Aim: </strong>To define associations between <i>H. pylori</i> in childhood and risk factors for gastric cancer with special emphasis on the role of family history of cancer.</p><p><strong>Methods: </strong>Details of 600 children who were subjected to upper gastrointestinal endoscopies at our institution are analyzed. Children were classified into positive and negative groups for <i>H. pylori</i> infection based on biopsy and rapid urease tests. The occurrences of gastric carcinoma, chronic superficial gastritis, glandular atrophy, and intestinal metaplasia among the groups are compared.</p><p><strong>Results: </strong>In our study, among the overall population, 330 children tested positive for <i>H. pylori</i>, which constituted 55% of the study population. The group denoting <i>H. pylori</i> positivity was found to have strikingly higher frequencies of chronic superficial gastritis (78.8% <i>vs</i> 5.9%), gastric atrophy (39.4% <i>vs</i> 7%), and intestinal metaplasia (0.9% <i>vs</i> 0%), as compared to the <i>H. pylori</i>-negative group. It is interesting to observe that there were a few but statistically significant cases of <i>H. pylori</i>-positive children having a family history of gastric cancer (1.2%), whereas no such cases were reported in children who were <i>H. pylori</i>-negative.</p><p><strong>Conclusion: </strong>Our study finds that <i>H. pylori</i> infection in childhood is associated with an increased risk of precancerous gastric conditions and that family history might provide an additional risk. These insights recommend the necessity of early <i>H. pylori</i> detection and intervention and management strategies in childhood, especially in those families with histories of gastric cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"103632"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}